State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 7,822,781 shares of Vir Biotechnology Inc common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 7,822,781 shares of Vir Biotechnology Inc common stock, representing 4.6% of the class.
  • Shared voting power: State Street disclosed shared power to vote or direct the vote of 7,507,527 shares, with sole voting power of 0 shares.
  • Shared dispositive power: The filing reported shared power to dispose of 7,822,781 shares, with sole dispositive power of 0 shares.
  • Triggering date: The event requiring the filing occurred on September 30, 2026.
  • Filing entity type: State Street Corporation identified itself as a parent holding company (type "HC") organized in Massachusetts.
  • Subsidiaries involved: The filing identified five investment adviser subsidiaries through which the position is held, including SSGA Funds Management, Inc. and State Street Global Advisors Europe Limited, among others.

State Street Corporation's Disclosed Stake in Vir Biotechnology as of September 30, 2026

State Street Corporation, headquartered at One Congress Street, Suite 1, Boston, MA 02114, submitted a Schedule 13G disclosing its beneficial ownership position in Vir Biotechnology Inc (CUSIP 92764N102), a company based at 499 Illinois Street, Suite 500, San Francisco, California 94158. According to the filing, the event triggering the disclosure occurred on September 30, 2026, and the statement was signed on November 9, 2026 by Alok Maheshwary, Senior Vice President.

The filing reported aggregate beneficial ownership of 7,822,781 shares, equal to 4.6% of the outstanding class of common stock. State Street disclosed no sole voting or sole dispositive power over any of these shares. Shared voting power covered 7,507,527 shares, while shared dispositive power extended to the full 7,822,781 shares, according to the filing.

State Street filed as a parent holding company pursuant to Rule 13d-1(b)(1)(ii)(G) and identified five subsidiaries classified as investment advisers (IA) through which the reported securities are held: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd. The filing also confirmed that Item 5 applies, noting ownership of 5 percent or less of the class, and certified that the securities "were acquired and are held in the ordinary course of business."

What Was Disclosed

State Street Corporation disclosed a 4.6% beneficial ownership stake, totaling 7,822,781 shares, in Vir Biotechnology Inc common stock as of September 30, 2026, held through five investment adviser subsidiaries with shared but no sole voting or dispositive power.